Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Sacituzumab tirumotecan + Cadonilimab in Second-Line Advanced Gastric/GEJ Adenocarcinoma
ChiCTR2600116847Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jan 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan and cadonilimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Objective Response Rate. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecancadonilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600116847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116847.